

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
April 30, 2026

DRAFT MEETING ROSTER

ACTING DESIGNATED FEDERAL OFFICER (Non-Voting)

Joyce Frimpong, PharmD

Division of Advisory Committee and Consultant Management
Office of Executive Programs, CDER, FDA

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Voting)

Toni K. Choueiri, MD

Director, Lank Center for Genitourinary Oncology
Professor, Harvard Medical School
Dana-Farber Cancer Institute
Boston, Massachusetts

William J. Gradishar, MD

(via video conferencing platform)
Betsy Bramsen Professor of Breast Oncology and
Professor of Medicine
Deputy Director, Clinical Network
Director, Maggie Daley Center for Women's Cancer
Care
Robert H. Lurie Comprehensive Cancer Center
Feinberg School of Medicine at
Northwestern University
Chicago, Illinois

Neil Vasan, MD, PhD

(Acting Chairperson)
Assistant Professor
Division of Hematology & Oncology
Department of Medicine
Herbert Irving Comprehensive Cancer Center
Columbia University Medical Center
New York, New York

ONCOLOGIC DRUGS ADVISORY COMMITTEE MEMBERS (Non-Voting)

Tara L. Frenkl, MD, MPH

Senior Vice President, Head of Global Medical
Strategy and Evidence Generation
Bayer Pharmaceuticals
Whippany, New Jersey

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
April 30, 2026

DRAFT MEETING ROSTER (cont.)

TEMPORARY MEMBERS (Voting)

Karla V. Ballman, PhD, FASCO

Professor, Biostatistics
Division Chair, Division of Clinical Trials &
Biostatistics
Mayo Clinic
Rochester, Minnesota

Sarah Colonna, MD, MSCI

(Morning Session Only)
Associate Professor, Medical Oncology,
Interim Co-Division Chief, Medical Oncology,
Medical Director of FCAC/Genetics
Huntsman Cancer Institute/University of Utah
Director, Comprehensive Genetics Services,
Veterans Affairs (VA) National Oncology Program
Salt Lake City, Utah

Natalie Compagni- Porits, PsyD, MFT

(Patient Representative; Morning Session Only)
Sonoma, California

Paul T. Conway

(Patient Representative)
Afternoon Session Only; via video conferencing
platform)
Falls Church, Virginia

Lori E. Dodd, PhD

(Morning Session Only)
Branch Chief
Clinical Trials Research and Statistics Branch
Office of Biostatistics Research
National Institute of Allergy and Infectious
Diseases
Bethesda, Maryland

Franklin Huang, MD, PhD

(Afternoon Session Only)
Associate Professor
Departments of Medicine and Urology
University of California San Francisco
Staff Physician, San Francisco Veterans Affairs
Medical Center (VAMC)
Scientific Director, Sierra Pacific Precision Oncology
Clinical Research Center
San Francisco, California

Fatima Karzai, MD

(Afternoon Session Only)
Senior Clinician, Genitourinary Malignancies
Branch
Deputy Clinical Director, Center for Cancer
Research, National Cancer Institute (NCI)
National Institutes of Health (NIH)

Michael J. Kelley, MD

(Morning Session Only)
Executive Director
National Oncology Program
Specialty Care Services, Veterans Health
Administration
Chief, Hematology/Oncology
Durham VAMC
Professor of Medicine
Duke University Medical Center
Durham, North Carolina

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
April 30, 2026

DRAFT MEETING ROSTER (cont.)

Stanely Lipkowitz, MD, PhD

(Morning Session Only)

Chief, Women's Malignancies Branch
Deputy Director, Center for Cancer Research
NCI, NIH
Bethesda, Maryland

Brian Rini, MD

(Afternoon Session Only, via video conferencing platform)

Professor of Medicine
Vanderbilt Ingram Cancer Center
Department of Hematology/Oncology
Vanderbilt University Medical Center
Nashville, Tennessee

Kyle Robinson, MD

(Afternoon Session Only)

Staff Physician
Corporal Michael J. Crescenz VA Medical Center
Associate Professor of Clinical Medicine
Division of Hematology-Oncology
University of Pennsylvania Perelman School of Medicine
Philadelphia, Pennsylvania

Aihua Edward Yen, MD

(Afternoon Session Only)

Assistant Professor
Department of Medicine, Section of Hematology/Oncology
Baylor College of Medicine
Genitourinary Medical Oncologist
Dan L Duncan Cancer Center
Houston VA Medical Center
Houston, Texas

FDA PARTICIPANTS (Non-Voting)

R. Angelo de Claro, MD

Director (Acting)
Oncology Center for Excellence, FDA

Director (Acting), Office of Oncologic Diseases
(OOD), CDER, FDA

Laleh Amiri-Kordestani, MD

Director
Division of Oncology 1 (DO1)
OOD, Office of New Drugs (OND), CDER, FDA

Daniel Suzman, MD

(Afternoon Session Only)

Deputy Director
DO1, OOD, OND, CDER, FDA

Mirat Shah, MD

(Morning Session Only)

Clinical Team Leader
DO1, OOD, OND, CDER, FDA

Elaine Chang, MD

(Afternoon Session Only)

Clinical Team Leader
DO1, OOD, OND, CDER, FDA

Joshua Donaldson, MD, PhD

(Morning Session Only)

Clinical Reviewer
DO1, OOD, OND, CDER, FDA

Suparna Wedam, MD

(Morning Session Only)

Clinical Reviewer
DO1, OOD, OND, CDER, FDA

Daniel Lee, MD, PhD

(Afternoon Session Only)

Clinical Reviewer
DO1, OOD, OND, CDER, FDA

FOOD AND DRUG ADMINISTRATION (FDA)
Center for Drug Evaluation and Research (CDER)

Oncologic Drugs Advisory Committee (ODAC) Meeting
April 30, 2026

DRAFT MEETING ROSTER (cont.)

Daeyoung Lim, PhD

(Morning Session Only)

Statistical Reviewer

Division of Biometrics V

Office of Biostatistics

Office of Translational Sciences

CDER, FDA

DRAFT